Novo Nordisk faces intensifying GLP-1 competition, notably from Eli Lilly, prompting price cuts for Wegovy to expand market access and defend share. NVO's long-term upside relies on broadening ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback